Fetal stem cell transplantation: Past, present, and future.
Fetal stem cell transplantation: Past, present, and future.
复制标题
DOI：
10.4252/wjsc.v6.i4.404
复制
发表时间：
2014-09-26
影响因子：
4.1
通讯作者：
Eto, Koji
中科院分区：
文献类型：
--
作者：
Ishii, Tetsuya;Eto, Koji
自1928年以来，人类胚胎组织和干细胞已在世界范围内用于治疗各种疾病。虽然移植胎儿中脑黑质和多巴胺能神经元的患者患有帕金森氏病是特别值得注意的，其他类型的移植物，如胎儿肝脏，胸腺和胰腺的历史，应解决有许多教训要吸取未来的干细胞移植。本报告描述了以前的做法和并发症，导致目前的临床试验分离胎儿干细胞和胚胎干细胞（ES）。此外，移植的策略被认为是，除了与胎儿起源相关的伦理问题，特别关注供体细胞，细胞处理和治疗细胞生态位。随着自体诱导多能干细胞和ES细胞的出现，尽管取得了里程碑式的成就，但由于持久的伦理争议，预计对胎儿移植的临床依赖性将逐渐下降。
Since 1928, human fetal tissues and stem cells have been used worldwide to treat various conditions. Although the transplantation of the fetal midbrain substantia nigra and dopaminergic neurons in patients suffering from Parkinson's disease is particularly noteworthy, the history of other types of grafts, such as those of the fetal liver, thymus, and pancreas, should be addressed as there are many lessons to be learnt for future stem cell transplantation. This report describes previous practices and complications that led to current clinical trials of isolated fetal stem cells and embryonic stem (ES) cells. Moreover, strategies for transplantation are considered, with a particular focus on donor cells, cell processing, and the therapeutic cell niche, in addition to ethical issues associated with fetal origin. With the advent of autologous induced pluripotent stem cells and ES cells, clinical dependence on fetal transplantation is expected to gradually decline due to lasting ethical controversies, despite landmark achievements.